Objective As the lack of reliable treatment for irritable bowel syndrome (IBS) prompts interest in the development of new therapies, we aimed to systematically evaluate the effect of Lactobacillus in treating this disease. Methods We searched MEDLIINE, PubMed, Scopus, Web of Science and the Cochrane Central Register of Controlled Trials for the period from 1966 to August 2013 for double-blind, placebo-controlled trials investigating the efficacy of Lactobacillus treatment in the management of IBS. The studies were screened for inclusion based on randomization, controls and reported measurable outcomes. We used the Jadad score to assess the quality of the articles. The STATA 11.0 and Revman 5.0 software packages were used for the metaanalysis. The STATA 11.0 software program was also used to assess indicators of publication bias according to Begg's and Egger's tests. Results Six randomized, placebo-controlled clinical trials met the criteria and were included in the metaanalysis. The Jadad score of the articles was >3, and three articles were of high quality. We analyzed the heterogeneity of the studies and found no heterogeneity in the meta-analysis. In the forest plot, the diamond was on the right side of the vertical line and did not intersect with the line. The pooled relative risk for clinical improvement with Lactobacillus treatment was 7.69 (95% confidence interval: 2.33-25.43, p=0.0008). For adults, the pooled relative risk for clinical improvement with Lactobacillus treatment was 17.62 (95% confidence interval: 5.12-60.65, p<0.00001). For children, the pooled relative risk for clinical improvement with Lactobacillus treatment was 3.71 (95% confidence interval:1.05-13.11, p=0.04). Using the STATA 10.0 and Revman 5.0 software programs, we confirmed that Lactobacillus exhibited significant efficacy in treating IBS. Conclusion Compared with the placebo, Lactobacillus treatment was found to be associated with a significantly higher rate of treatment responders in the overall population with IBS, without any side effects. As to limitations of the analysis, additional research is needed. ) the physiopathology of IBS has not been elucidated, likely due to the large number of factors involved, such as the en-
Introduction
Irritable bowel syndrome (IBS) is a functional disorder of the digestive tract that causes chronic symptoms, such as abdominal pain and discomfort, and abnormal bowel movements, including diarrhea and constipation, with no organic abnormalities (1) . IBS is one of the most frequent digestive tract disorders encountered by general practitioners and gastroenterologists. However, its etiology remains unknown. The most popular pathogenetic theory involves a combination of dysregulated gastrointestinal (GI) motility and heightened visceral sensitivity in the context of chronic life stressors and other psychological factors (2) . Nevertheless, teric nervous system, inflammatory processes, diet and (recognized more recently) microbiota. In patients with IBS, constipation can be acute or chronic, with chronic constipation defined as that with a duration greater than three months. The Rome III criteria for chronic constipation include the presence of two or more of six symptoms for at least 12 weeks within the preceding six months (1. straining at defecation on at least 1/4 occasions; 2. lumpy/hard stools on at least 1/4 occasions; 3. the sensation of incomplete evacuation on at least 1/4 occasions; 4. the need for manual maneuvers to facilitate defecation on at least 25% of occasions; 5. the sensation of anorectal obstruction/blockage on at least 25% of occasions; 6. fewer than three bowel movements a week).
Despite the findings of numerous studies targeting treatment for IBS (3, 4) , there is currently no universally accepted satisfactory treatment protocol for this condition. Recently, the administration of probiotics, defined as live microorganisms that, when administered in adequate amounts, confer a health benefit on the host (5), has been proposed as a treatment for functional gastrointestinal disorders. Probiotics have been shown to have beneficial effects on various aspects of human health, as well as several gastrointestinal disorders, including adult and pediatric diarrhea, antibioticassociated diarrhea and pouchitis (6) .
Four meta-analyses (7-10) have previously evaluated the effects of probiotics for the treatment of IBS, primarily in adult populations, with each reaching slightly different conclusions. Currently, Lactobacilli and Bifidobacteria are among the most commonly studied probiotics in patients with IBS (11) . Regarding the pediatric population, a Cochrane systematic review (12) concluded that there is no evidence that Lactobacillus supplementation is effective in managing children with recurrent abdominal pain. We therefore performed a meta-analysis of randomized controlled trials to assess whether there are any benefits to Lactobacillus treatment in improving symptoms and/or the health-related quality of life in patients with IBS, among both adults and children.
Materials and Methods

Search strategy
We searched MEDLINE, PubMed, Scopus, Web of Science and the Cochrane Central Register of Controlled Trials for studies investigating the efficacy of Lactobacillus supplementation for treating IBS. Data were collected from 1966 to 2013 (up to August). The search terms were as follows: "Lactobacillus" or "lactic acid bacteria" and "irritable bowel,""functional bowel diseases" or "irritable colon." The search was restricted to the English-language literature. We searched the references of the reviewed articles for additional articles missed in the computerized database search. All primary and review articles, as well as their references, were reviewed independently in duplicate.
Study selection
All controlled trials investigating the efficacy of Lactobacillus therapy in patients with IBS were considered. The studies were screened for inclusion through a review of the published articles based on the following criteria: randomization, controls and reported measurable outcomes. Each article was reviewed in duplicate for inclusion, with substantial inter-rater agreement. A trial was disqualified if it was not controlled or its outcomes did not consider efficacy. The reviewers independently extracted data for patient characteristics, therapeutic regimens, dosages, trial duration and outcome measures.
Methodology quality assessment
We used the Jadad score to assess the quality of each article. The Jadad score, which evaluates studies based on their description of randomization, blinding and dropouts (withdrawals), was used to determine the methodological quality of the trials (13) . The quality scale ranged from 0 to 5 points, with a low quality report indicated by a score of ! 2 and a high quality report indicated by a score of " 4.
Data synthesis and statistical analysis
All analyses were performed using the STATA Software (version 11.0, Stata Corporation, College Station, USA) and Revman (version 5.0, The Cochrane Collaboration, Oxford, UK). Data from selected studies were extracted into 2×2 tables. All included studies were weighted and pooled. The relative risk (odds ratio; OR) and 95% confidence interval (CI) were calculated, and an effect size (weighted mean difference) meta-analysis was performed using the STATA 11.0 and Revman 5.0 programs. The event rate in the experimental (intervention) group against that in the control group was calculated using a l'Abbe plot as an aid to explore the heterogeneity of the effect estimates. In cases of homogeneity, a fixed-effects model was used for the meta-analysis; otherwise, the random-effects model was applied.
Publication bias
The STATA 11.0 program was used to identify indicators of publication bias according to Begg's and Egger's tests. A p value of " 0.05 indicated the absence of publication bias. In addition to Kendall's t-test (14) , funnel plots were used to identify indicators of publication bias (15) .
Results
Article selection
The literature search identified 67 citations involving Lactobacillus and IBS, six of which met our inclusion criteria (11, (16) (17) (18) (19) (20) . Of the 61 excluded articles, 18 were review articles, two were observational studies comparing Lactobacillus supplementation with other medicines, three were animal experiments, four were not in English, three were arti- Not only about lactobacillus n=31
Can not access n=3
Not in English n=4 6 articles were included.
cles that could not be accessed and 31 included combined treatment ( Fig. 1) .
Jadad score assessment
The quality of the seven selected studies was assessed according to the Jadad score (Table 1) . Three studies had a score of 3, and three studies had a score of 4. So therefore, six articles were of high quality.
The patient characteristics, IBS subtype, dose, side effects and duration of treatment/follow-up in each study are reported in Table 2 . All subtypes of IBS (diarrheapredominant, constipation-predominant and alternating) were incorporated in the included studies. The meta-analysis in-cluded 440 IBS patients (273 adults and 167 children) randomized to receive either Lactobacillus or a placebo. The definition of a clinical response in each study is reported in Table 3 .
The Rome III criteria for IBS are presented in Table 4 .
Heterogeneity test
We performed the heterogeneity analysis using the χ 2 test. χ 2 =26.58, p<0.0001 (Fig. 2) , χ 2 =4.52, p=0.10 (Fig. 3) , χ 2 = 6.21, p=0.04 ( Fig. 4) and found heterogeneity in the metaanalysis. Therefore, a random-effects model was used for the meta-analysis. The cause of heterogeneity may be the limited number of studies and small sample sizes. Abdominal discomfort** or pain associated with two or more of the following at least 25% of the time: a. Improvement with defecation b. Onset associated with a change in frequency of stool c. Onset associated with a change in form (appearance) of stool No evidence of an inflammatory, anatomic, metabolic, or neoplastic process that explains the subject's symptoms *Criteria fulfilled at least once per week for at least 3 months prior to diagnosis **"Discomfort" means an uncomfortable sensation not described as pain. 
Figure 2. Effects of Lactobacillus in the IBS patients
Publication bias assessment
The reasons for publication bias include the fact that positive results were published easily, whereas negative results were not. Alternatively, negative results may have caused the researchers to abandon their studies, meaning that the negative results were not published, thus affecting the metaanalysis. In our analysis, we performed Begg's test ( Fig. 5A ) and Egger's test (Fig. 5B) , both of which showed no publication bias in the meta-analysis (Begg's test, p= 1.000; Egger's test, p=0.932).
Merging and meta-analysis
The meta-analysis showed that the heterogeneity among the six studies was statistically significant (p<0.0001); therefore, we performed the random-effects model for the metaanalysis. In the forest plot, the diamond was on the right side of the vertical line and did not intersect with the line. As shown in Fig. 2 , the OR was 7.69 (95%CI: 2.33-25.43, z=3.35, p=0.0008) (Fig. 2) , which indicated that Lactobacillus supplementation had an effect on irritable bowel syndrome. As shown in Fig. 3 , when we used the randomeffects model for the meta-analysis (p=0.10), the OR was 17.62 (95%CI: 5.12-60.65, z=4.55, p<0.00001), which indicated that Lactobacillus treatment had an effect in the adult irritable bowel syndrome patients. In Fig. 4 , we applied the random-effects model for the meta-analysis (p=0.04) and found an OR of 3.71 (95%CI: 1.05-13.11, z=2.04, p=0.04), which indicated that Lactobacillus therapy had an effect in the pediatric irritable bowel syndrome patients. However, because the number of included articles was limited, further research and analysis is required in the future. Sinn DH et al [11] ,2008
Zeng J et al [19] ,2008
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.83; Chi² = 6.21, df = 2 (p = 0.04); I² = 68% Test for overall effect: Z = 2.04 (p = 0.04) 
Discussion
IBS is a functional bowel disorder characterized by chronic and relapsing abdominal pain or discomfort associated with altered bowel habits. The primary aim of treatment is to relieve abdominal pain, which can impair the patient's quality of life. Affected patients experience recurrent abdominal pain and/or discomfort with alterations in bowel habits in addition to a range of other features, including bloating, distension, flatulence, borborygmi and disturbances in the defecatory function (21) . The therapeutic efficacy of IBS treatment is likely impacted by the heterogeneous pathogenesis of the disease, which includes altered intestinal motility, visceral hypersensitivity, abnormal brain-gut interactions, food intolerance, altered intestinal permeability and post-infectious and/or inflammatory changes (22) . Due to its obscure pathophysiology, treating IBS remains difficult, prompting interest in the identification of new and safe treatment options.
According to published guidelines, the primary treatment options for abdominal pain include antispasmodics or antidepressants at low doses, while anti-diarrheal and/or laxative drugs are given to improve transit disturbances (23, 24) . However, some of these drugs have a narrow therapeutic window, including antidepressants, alosetron and tegaserod, which limits their clinical application, especially in mild cases of IBS (25) . In contrast, probiotics are composed of normal gut flora, and adverse events associated with these agents are very rare. Therefore, probiotics are good candidates for controlling the symptoms associated with IBS, especially when treatment safety is paramount in non-lethal disorders, such as IBS (26) . While the exact mechanisms by which probiotics exert their effects in patients with IBS are not fully understood, several potential mechanisms have been suggested. As Lactobacillus is currently a popular probiotic, we accumulated data and conducted an analysis of the treatment efficacy of Lactobacillus supplementation.
In our research, we found six articles that met the inclusion criteria, including three articles about children and three articles about adults. According to the results of the metaanalysis, Lactobacillus treatment has an effect in both children and adults with IBS, without any side effects. In addition, the meta-analysis showed that the level of heterogeneity was statistically significant; therefore, we performed a random-effects model analysis. The heterogeneity observed in this study may have been due to the patient's age or dose or duration of medication. The random-effects model was more accurate for the analysis. Furthermore, this metaanalysis showed that Lactobacillus therapy is beneficial in IBS patients, although the mechanism of action underlying this benefit remains a matter of debate. While IBS is likely Begg's Test multifactorial in etiology, recent findings in both experimental animal and clinical studies suggest that disturbances in gut flora, as observed in the setting of small-intestinal bacterial overgrowth, occur in patients with irritable bowel syn-drome and that such abnormalities contribute to the development of IBS-type symptoms. However, this review is associated with some limitations. Our results are considered preliminary, and our findings must be confirmed in additional studies. In addition, the data are insufficient to recommend this method of treatment as a first-line therapy or to evaluate long-term results. Therefore, further research is required to more accurately assess the outcomes and mechanism of action of Lactobacillus treatment in cases of IBS. As the exact mechanism of action of Lactobacillus therapy remains unknown, further experimental studies are desirable.
Conclusion
Lactobacillus is a good candidate for assessment in a large multicenter trial of IBS patients, including both adults and children. With respect to the limitations of this metaanalysis, there is a strong need for further research to confirm the effects of probiotic treatment. As the exact mechanism of action of Lactobacillus supplementation is not known, further experimental studies are needed.
